Genmab A/S Stock

Genmab A/S Working Capital

The Working Capital of Genmab A/S (GMAB.CO) as of Aug 5, 2026 is 1.46 B USD. In the previous year, Working Capital was 3.13 B USD — a change of -53.42% (lower).

Working Capital

1.46 BUSD

YoY

-53.42%

Last updated:

Working Capital of Genmab A/S is 2026 1.46 B USD. Working Capital of Genmab A/S was 2025 3.13 B USD. It decreases by -53.42% lower compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Working Capital of Genmab A/S is 1.46 B USD in 2026.

Working Capital of Genmab A/S changed from 3.13 B USD to 1.46 B USD, representing a -53.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Genmab A/S historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Genmab A/S

All Key Metrics — Genmab A/S